AstraZeneca to add small molecule drug factory in WND

AstraZeneca's Wuxi production base in Wuxi New District. [Photo/WeChat account: xinwu_wx]

Pharmaceutical and biotechnology company AstraZeneca signed a cooperation agreement with Wuxi in Jiangsu province for the construction of a new factory specializing in small molecule drugs on March 1.

With a total investment of $475 million, the factory plans to equip itself with cutting-edge tablet manufacturing equipment and sustainable drug packaging production lines. Once completed, it will further enhance its small molecule drug production capacity. Leveraging the advantages of the group's global supply network, the factory aims to supply products to both the Chinese and global markets, benefiting a larger number of patients.

Additionally, AstraZeneca strives to build a smart and zero-carbon factory, positioning Wuxi as one of its global production and supply bases.

Pascal Soriot, CEO of AstraZeneca, stated that Wuxi has been the starting point for the group's development in China over the past 30 years. The city's rapid economic growth and achievements in technological innovation have left an indelible mark, solidifying AstraZeneca's confidence and determination to continue its presence and investment in Wuxi.

Soriot also emphasized the importance of accelerating the completion and operation of the new factory. AstraZeneca is committed to deepening cooperation with Wuxi in areas such as green and low-carbon technologies, digital healthcare, and industrial funds, as well as contributing to talent cultivation and exports of pharmaceutical products.

AstraZeneca hosts a zero-carbon innovation forum during the signing ceremony. [Photo/WeChat account: xinwu_wx]

On the same day, AstraZeneca and the Wuxi government also hosted a forum, inviting nearly a hundred professionals from Fortune 500 companies, international organizations, consulting firms, and government departments to explore new pathways for sustainable development in China's biopharmaceutical and healthcare industries.

Having deepened its roots in Wuxi for over 30 years, AstraZeneca has consistently increased its investment. In recent years, it has successively established production, distribution, sales, and innovation headquarters in Wuxi, becoming a leading enterprise in the city's biopharmaceutical industry.